Immunovia Publishes Interim Report Jan-June 2022
April-June 2022 · Net sales amounted to kSEK 103 (38) divided between sales of tests kSEK 45 and royalties kSEK 58 · Net earnings amounted to MSEK -33 (-49) and earnings per share before and after dilution were SEK -1.49 (-2.18) · Cash flow from operating activities amounted to MSEK -41 (-34) · Cash and cash equivalents at the end of the period amounted to MSEK 197 (382) · In April Immunovia submitted the application for CPT PLA Code for the IMMray™ PanCan-d test · The Annual General Meeting on April 7th elected Eric Krafft and Philipp von Hugo as new board members.
